Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:2:55-62.
doi: 10.2147/ibpc.s6232. Epub 2009 Nov 23.

Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors

Alberto F Rubio-Guerra  1 , David Castro-Serna, Cesar I Elizalde Barrera, Luz M Ramos-Brizuela
Affiliations

Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors

Alberto F Rubio-Guerra et al. Integr Blood Press Control. 2009.

Abstract

Recent guidelines for the management of hypertension recommend target blood pressures <140/90 mmHg in hypertensive patients, or <130/80 mmHg in subjects with diabetes, chronic kidney disease, or coronary artery disease. Despite the availability and efficacy of antihypertensive drugs, most hypertensive patients do not reach the recommended treatment targets with monotherapy, making combination therapy necessary to achieve the therapeutic goal. Combination therapy with 2 or more agents is the most effective method for achieving strict blood pressure goals. Fixed-dose combination simplifies treatment, reduces costs, and improves adherence. There are many drug choices for combination therapy, but few data are available about the efficacy and safety of some specific combinations. Combination therapy of calcium antagonists and inhibitors of the renin-angiotensin-aldosterone system (RAAS) are efficacious and safe, and have been considered rational by both the JNC 7 and the 2007 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. The aim of this review is to discuss some relevant issues about the use of combinations with calcium channel blockers and RAAS inhibitors in the treatment of hypertension.

Keywords: adherence; calcium channel blockers; fixed-dose combination; hypertension; renin-angiotensin-aldosterone system inhibitors.

PubMed Disclaimer

References

    1. The Seventh report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood pressure. JNC 7. Hypertension. 2003;42:1206–1252. - PubMed
    1. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults, 1999–2004. Hypertension. 2007;49:69–75. - PubMed
    1. Rosas M, Lara A, Pastelín G, Velásquez O, Martínez J, Mendez A. Re-encuesta nacional de hipertensión arterial. Consolidación Mexicana de los factores de riesgo cardiovascular. Cohorte Nacional de Seguimiento. Arch Cardiol Mex. 2005;75:96–111. - PubMed
    1. Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vasc Health Risk Manag. 2008;4:653–664. - PMC - PubMed
    1. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290–300. - PubMed